Three hub genes (CXCL9, IL2RB, and SPP1) serve as potential biomarkers for the diagnosis of the comorbidities of AS and NASH, either independently or in combination, with a certain degree of accuracy and specificity. Here, CXCL9 is linked to metabolic dysfunction-associated steatohepatitis.